Hydroxyzine for Anxiety and Depression
Hydroxyzine is FDA-approved and evidence-supported for treating anxiety, but it is NOT indicated for depression and should not be used as a primary treatment for depressive disorders. 1
FDA-Approved Indication for Anxiety
Hydroxyzine is specifically approved for "symptomatic relief of anxiety and tension associated with psychoneurosis" 1. The FDA label explicitly recognizes its role in anxiety management, though it notes that effectiveness beyond 4 months has not been systematically assessed 1.
Evidence for Anxiety Treatment
The evidence supports hydroxyzine's efficacy in generalized anxiety disorder (GAD):
A 3-month randomized controlled trial demonstrated hydroxyzine 50 mg/day was superior to placebo, with mean HAM-A score improvements of -12.16 vs -9.64 (p=0.019), along with better responder rates (p=0.003) and remission rates (p=0.028) 2
A Cochrane systematic review of 5 studies (884 participants) found hydroxyzine more effective than placebo for GAD (OR 0.30,95% CI 0.15-0.58), though the authors noted high risk of bias in included studies 3
Hydroxyzine performed comparably to benzodiazepines and buspirone in head-to-head trials, with similar efficacy but potentially better safety profile than benzodiazepines 2, 4
NOT for Depression
Depression requires antidepressants as first-line treatment. Current guidelines recommend second-generation antidepressants (SSRIs, SNRIs) for major depressive disorder 5. Hydroxyzine has no established role in treating depression and should not be substituted for evidence-based antidepressant therapy.
Interestingly, one animal study suggested that combining hydroxyzine with SSRIs (unlike benzodiazepines) did not interfere with antidepressant efficacy 6, but this does not establish hydroxyzine as a depression treatment—it merely suggests it may be safer than benzodiazepines when anxiolytic augmentation is needed in depressed patients.
Critical Safety Considerations
QT prolongation risk: Hydroxyzine can cause QT prolongation and Torsade de Pointes, particularly in patients with pre-existing cardiac risk factors, electrolyte imbalances, or concurrent use of other QT-prolonging drugs (including certain antidepressants like citalopram and fluoxetine) 1
Sedation and CNS depression: Expect significant drowsiness—this potentiates other CNS depressants and impairs driving ability 1. In elderly patients, start with low doses due to increased risk of confusion and over-sedation 1.
Common adverse effects: Drowsiness is the predominant side effect. Studies show hydroxyzine and cetirizine may negatively impact mood states compared to newer antihistamines 7.
Practical Algorithm
For anxiety alone: Hydroxyzine 25-50 mg at bedtime or divided doses can be considered, particularly for short-term use (≤4 months) or when benzodiazepines are contraindicated 1, 2
For depression with comorbid anxiety: Use an SSRI or SNRI as primary treatment 5. If residual anxiety persists despite adequate antidepressant trial, hydroxyzine may be added cautiously for anxiety symptoms, but monitor for QT interactions with certain SSRIs 1
For depression alone: Do NOT use hydroxyzine—prescribe an evidence-based antidepressant and continue for 4-9 months after response (longer for recurrent episodes) 5